ABI news agency noted that the Havana-based Finlay Vaccines Institute (IFV)) reported the conclusion of that part of the study, which involved 350 children and adolescents who volunteered to receive the first dose of the vaccine. The trial, called Soberana Pediatrics, began on June 14 and has shown high safety rates, with no records of serious adverse events, the scientific institution confirmed.
The sample of candidates is divided into two groups, one made up of adolescents aged 12-18, and another group of children between 3 and 11 years of age.
ABI pointed out that according to the IFV, Soberana Pediatrics is a two-phase study, each one corresponding to a dose of the Soberana 02 vaccine candidate, in addition to one dose of Soberana Plus to complete the immunization schedule.
Cuba has developed four vaccine candidates (Soberana 01 and 02, Soberana Plus and Mambisa), and with Abdala as the vaccine approved by relevant authorities, it is the only country in Latin America with its own vaccines to deal with the SARS-CoV-2 virus, which causes Covid-19, and its variants.